Anifrolumab for the treatment of refractory chilblain lupus erythematosus
JAAD Case Rep
.
2023 Nov 4:48:69-71.
doi: 10.1016/j.jdcr.2023.10.020.
eCollection 2024 Jun.
Authors
Michael J Woodbury
1
,
Katherine Nabel Smith
1
,
Jeffrey S Smith
1
,
Joseph F Merola
2
Affiliations
1
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
2
Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas.
PMID:
38778891
PMCID:
PMC11108794
DOI:
10.1016/j.jdcr.2023.10.020
No abstract available
Keywords:
anifrolumab; chilblain lupus erythematosus; type I interferon.
Publication types
Case Reports